Related Experiment Video

Updated: Mar 20, 2026

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
06:08

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

3.0K

Targeting adipose tissue in the treatment of obesity-associated diabetes

Christine M Kusminski1, Perry E Bickel2, Philipp E Scherer1

  • 1Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center.

Nature Reviews. Drug Discovery
|June 4, 2016
PubMed

Insights

Adipose tissue dysfunction in obesity disrupts metabolic homeostasis and leads to type 2 diabetes mellitus (T2DM). This review explores novel therapeutic strategies targeting adipose tissue for improved metabolic health.

Area of Science:

  • Metabolic physiology
  • Obesity research
  • Endocrinology

Background:

  • Adipose tissue is crucial for metabolic homeostasis.
  • Obesity-associated adipose tissue dysfunction contributes to insulin resistance and type 2 diabetes mellitus (T2DM).
  • Current T2DM treatments have limitations in efficacy and side effects.

Purpose of the Study:

  • To review the role of adipose tissue in metabolic homeostasis.
  • To assess novel therapeutic strategies for obesity and T2DM targeting adipose tissue.

Main Methods:

  • Literature review of adipose tissue function.
  • Analysis of emerging therapeutic targets for metabolic diseases.

Main Results:

  • Adipose tissue dysfunction is central to metabolic disruption in obesity.
  • Novel strategies include adipokine-based therapies, promoting white adipose tissue beiging, and reducing inflammation/fibrosis.

Conclusions:

  • Targeting adipose tissue offers promising avenues for treating obesity and T2DM.
  • Future therapies may improve long-term glucose control and reduce adverse effects.

More Related Videos

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue10:28

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue

Published on: July 17, 2018

12.6K
Localization, Identification, and Excision of Murine Adipose Depots08:53

Localization, Identification, and Excision of Murine Adipose Depots

Published on: December 4, 2014

42.3K

Related Concept Videos

Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
891
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
358
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K